BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:40 PM
Nov 04, 2008
 |  BC Extra  |  Clinical News

YM reports nimotuzumab data

YM BioSciences (TSX:YM; AMEX:YMI) reported preliminary data from two ongoing trials of nimotuzumab late Monday. In a Phase II/III trial in newly diagnosed high-grade glioma patients, the mean and median survival time for nimotuzumab plus radiotherapy were 14.3 and...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >